STOCK TITAN
  1. Home
  2. Sec-filings
  3. LUCY
  4. [Form 4] Innovative Eyewear Inc Insider Trading Activity

Innovative Eyewear (LUCY) CFO sells 15,533 shares after grants

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Innovative Eyewear Inc (LUCY) reported that Chief Financial Officer Gayle Oswald received two grants of 16,233 shares of common stock on April 2, 2026 and August 19, 2026 at $0.00 per share. On the same respective dates, she sold 7,574 shares at a $1.0725 average price and 7,959 shares at a $0.6745 average price in open market or private transactions. The filing’s Rule 10b5-1 checkbox is not marked as being pursuant to a trading plan, and it does not state her total holdings after these transactions.

Positive

  • None.

Negative

  • None.
Insider Gayle Oswald
Role Chief Financial Officer
Sold 15,533 shs ($13K)
Type Security Shares Price Value
Grant/Award Common Stock 16,233 $0.00 $0.00
Sale Common Stock F2 7,959 $0.6745 $5K
Grant/Award Common Stock 16,233 $0.00 $0.00
Sale Common Stock F1 7,574 $1.0725 $8K
Holdings After Transaction: Common Stock — 19,798 shares (Direct)
Footnotes (2)
  1. F1. The price reported in Column 4 is an average price of $1.0725. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  2. F2. The price reported in Column 4 is an average price of $0.6745. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Shares granted April 2, 2026 16,233 shares of Common Stock at $0.0000 per share Grant, award, or other acquisition on 2026-04-02
Shares sold April 2, 2026 7,574 shares of Common Stock at $1.0725 per share (average price) Sale in open market or private transaction on 2026-04-02
Shares granted August 19, 2026 16,233 shares of Common Stock at $0.0000 per share Grant, award, or other acquisition on 2026-08-19
Shares sold August 19, 2026 7,959 shares of Common Stock at $0.6745 per share (average price) Sale in open market or private transaction on 2026-08-19
Total shares sold in reported period 15,533 shares of Common Stock Combined sales on 2026-04-02 and 2026-08-19
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
Sale in open market or private transaction financial
"transaction_code_description: Sale in open market or private transaction"
weighted average price financial
"The price reported in Column 4 is an average price of $1.0725."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

What insider transactions did LUCY’s CFO Gayle Oswald report on this Form 4?
Gayle Oswald reported two stock grants of 16,233 common shares each on April 2, 2026 and August 19, 2026, both at $0.00 per share, and same-day sales of 7,574 shares and 7,959 shares at weighted average prices of $1.0725 and $0.6745, respectively.

How many LUCY shares did the CFO sell according to this Form 4?
The Form 4 reports that Gayle Oswald sold a total of 15,533 shares of Innovative Eyewear Inc common stock, consisting of 7,574 shares sold on April 2, 2026 and 7,959 shares sold on August 19, 2026.

What prices did the LUCY CFO receive for the reported stock sales?
The filing states that the April 2, 2026 sale had a $1.0725 weighted average price per share and the August 19, 2026 sale had a $0.6745 weighted average price per share. Footnotes explain these are average prices and that detailed trade prices are available on request.

Were the LUCY CFO’s trades made under a Rule 10b5-1 trading plan?
The document-level Rule 10b5-1 checkbox is not checked, and the footnotes do not describe a trading plan. Based on this filing, the reported transactions are not affirmed as being made pursuant to a Rule 10b5-1 trading plan.

Did the LUCY CFO report any derivative securities on this Form 4?
No derivative securities are reported. All transactions in this Form 4 involve non-derivative common stock, with grants at $0.00 per share and sales at weighted average market prices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gayle Oswald
(Last)(First)(Middle)
C/O INNOVATIVE EYEWEAR INC.
11900 BISCAYNE BLVD., SUITE 630
(Street)
MIAMI FLORIDA 33181
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Innovative Eyewear Inc [ LUCY ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/02/2026A16,233A$0.0019,098D
Common Stock04/02/2026S7,574D$1.0725(1)11,524D
Common Stock08/19/2026A16,233A$0.0027,757D
Common Stock08/19/2026S7,959D$0.6745(2)19,798D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is an average price of $1.0725. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
2. The price reported in Column 4 is an average price of $0.6745. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
/s/ Oswald Gayle08/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR